Phase Ib Trial of Copanlisib, A Phosphoinositide-3 Kinase (PI3K) Inhibitor, with Trastuzumab in Advanced Pre-Treated HER2-Positive Breast Cancer “PantHER”

SIMPLE SUMMARY: Patients with HER-2 positive breast cancer who progress through available HER2-targeted therapy, at present, have few effective treatment options. PIK3CA is mutated in approximately 20% of HER2 positive breast cancers, contributes to HER-2 therapy resistance and may be predictive of...

Description complète

Enregistré dans:
Détails bibliographiques
Publié dans:Cancers (Basel)
Auteurs principaux: Keegan, Niamh M., Furney, Simon J., Walshe, Janice M., Gullo, Giuseppe, Kennedy, M. John, Smith, Diarmuid, McCaffrey, John, Kelly, Catherine M., Egan, Keith, Kerr, Jennifer, Given, Mark, O’Donovan, Peter, Hernando, Andres, Teiserskiene, Ausra, Parker, Imelda, Kay, Elaine, Farrelly, Angela, Carr, Aoife, Calzaferri, Giulio, McDermott, Ray, Keane, Maccon M., Grogan, Liam, Breathnach, Oscar, Morris, Patrick G., Toomey, Sinead, Hennessy, Bryan T.
Format: Artigo
Langue:Inglês
Publié: MDPI 2021
Sujets:
Article
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC7999809/
https://ncbi.nlm.nih.gov/pubmed/33799597
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3390/cancers13061225
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires